Actively Recruiting
P-CABs-based Bismuth Quadruple Therapy for Helicobacter Pylori Eradication
Led by Yueyue Li · Updated on 2025-12-23
1730
Participants Needed
1
Research Sites
32 weeks
Total Duration
On this page
Sponsors
Y
Yueyue Li
Lead Sponsor
Q
Qilu Hospital of Shandong University
Collaborating Sponsor
AI-Summary
What this Trial Is About
Bismuth-containing quadruple therapy was recommended as a first-line treatment for Helicobacter pylori infection. This study aimed to compare real-world outcomes of various potassium-competitive acid blockers (P-CABs) -based bismuth quadruple regimens and identify factors influencing treatment failure. A multicenter cohort study was conducted and study outcomes included eradication rates and incidence of adverse events.
CONDITIONS
Official Title
P-CABs-based Bismuth Quadruple Therapy for Helicobacter Pylori Eradication
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients aged 18 to 70 years, any gender
- Willing to receive Helicobacter pylori eradication therapy
- Diagnosed with Helicobacter pylori infection by rapid urease test, 13C/14C-urea breath test, or histopathological exam
You will not qualify if you...
- Incomplete medical records, including missing treatment details or follow-up test results
- Treatment regimens not following the specified quadruple regimens in this study
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Qilu Hospital of Shandong University
Jinan, China
Actively Recruiting
Research Team
Y
Yueyue Li
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here